Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Prostrakan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01073696
First received: February 16, 2010
Last updated: September 24, 2010
Last verified: February 2010

February 16, 2010
September 24, 2010
March 2010
April 2010   (final data collection date for primary outcome measure)
Pharmacokinetic profile of the granisetron patch in healthy subjects when heat is applied [ Time Frame: 0 - 196 hours post dose ] [ Designated as safety issue: No ]
To assess the effect of locally applied heat on the pharmacokinetic profile of granisetron delivered from the patch. Subjects will be randomized to receive Treatment A Sancuso patch ONLY and Treatment B, Sancuso PLUS Cura-Heat pad. Sancuso will be worn by the subjects for 5 days continuously. The Cura-Heat pad will be applied over the patch for 4.5 hours on each of the 5 days. During these 5 days PK sampling is planned to measure the initial release of granisetron from the patch and cover the predicted maximum observed concentrations with or without the Cura-Heat pad in place.
Same as current
Complete list of historical versions of study NCT01073696 on ClinicalTrials.gov Archive Site
  • Safety and tolerability assessment [ Time Frame: Up to 23 days post dose ] [ Designated as safety issue: Yes ]
    Safety and tolerability will be assessed by collection of adverse events, safety laboratory assessments, record of vital signs, conduct of physical examination and 12 lead ECG. In addition skin reaction at the patch and Cura-Heat pad application sites will be monitored.
  • residual granisetron after patch use in healthy subjects [ Time Frame: 120 hours post dose ] [ Designated as safety issue: No ]
    • Residual granisetron after patch use and the calculation of in-vitro flux will be measured. All used patches will be returned to the manufacturer who will measure the amount of remaining granisetron in the patch and then the in-vitro flux will be calculated as follows: Amount delivered(assay amount-residual)/ number of days the patch was applied to the skin
Same as current
Not Provided
Not Provided
 
Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects
A Phase I Study to Evaluate the Effect of External Heat on the Pharmacokinetics of a Transdermal Granisetron Patch in Healthy Subjects

The purpose of this study is to determine the effect of heat applied to a granisetron transdermal patch in healthy subjects.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy
  • Drug: granisetron IV
    IV
  • Drug: granisetron patch
    patch
  • Active Comparator: granisetron IV
    Intervention: Drug: granisetron IV
  • Experimental: granisetron patch
    Intervention: Drug: granisetron patch
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male or female subjects aged ≥ 18 and ≤ 45 years at screening. Subjects must demonstrate understanding of the purposes and risks of the study and agree to follow the restrictions and schedule of study procedures, as evidenced by voluntary written informed consent (signed and dated) obtained before taking part in any trial-related activities.

Exclusion Criteria:

  • Any current or previous disease, disorder, allergy or condition (including recent unexplained weight loss) that could affect the study conduct or laboratory assessments, or that presents undue risk from the study medication or procedures. Hypersensitivity to adhesive plasters or surgical tape.
  • Any physical examination or screening investigation result that indicates the subject is unfit for the study.
  • Scarring on upper arms, including extensive tattoos making skin reactions unevaluable.
  • A positive virology test, urine test for drugs of abuse, or pregnancy test result (females of childbearing potential only).
  • Recent use of prescribed or over-the-counter medication that, in the opinion of the Investigator or the Sponsor, will interfere with the study procedures or compromise safety.
  • Received an investigational drug within 3 months (90 days) preceding patch application.
  • Loss of ≥ 400 mL of blood (e.g. been a blood donor) within the past 3 months.
  • Average weekly alcohol consumption of greater than 21 units (males) or 14 units (females), or habitually smokes ≥ 5 cigarettes or equivalent tobacco per day within the 6 months before patch application. Subjects may not smoke while confined to the study site. Subjects must not consume alcohol, or xanthine-containing foods or drinks within 48 hours prior to dosing until discharge.
  • Lactating female subjects, and female subjects of childbearing potential who are not willing to use an acceptable form of contraception from the screening visit, during the study and for 90 days after the study.
  • Employee of the Investigator or study centre, with direct involvement in the proposed study or other studies under the direction of that Investigator or study centre, as well as family members of the employees or the Investigator.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01073696
392MD/43/C, 2009-017036-40
No
Dr. Stuart J Mair, Quotient Clinical LImited
Prostrakan Pharmaceuticals
Not Provided
Principal Investigator: Stuart J Mair Quotient Clinical Limited
Prostrakan Pharmaceuticals
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP